STOCK TITAN

MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

MannKind (Nasdaq: MNKD) will host a conference call to discuss its 2024 first quarter financial results on May 8, 2024. Interested parties can listen live on the Company's website.

MannKind (Nasdaq: MNKD) organizzerà una teleconferenza per discutere i risultati finanziari del primo trimestre del 2024 l'8 maggio 2024. Le parti interessate possono ascoltare in diretta sul sito web della società.
MannKind (Nasdaq: MNKD) realizará una llamada de conferencia para discutir los resultados financieros del primer trimestre de 2024 el 8 de mayo de 2024. Las partes interesadas pueden escuchar en vivo en el sitio web de la Compañía.
맨카인드(Nasdaq: MNKD)는 2024년 5월 8일에 2024년 1분기 재무 결과에 관해 논의하기 위한 컨퍼런스 콜을 개최할 예정입니다. 관심 있는 당사자는 회사 웹사이트에서 실시간으로 청취할 수 있습니다.
MannKind (Nasdaq: MNKD) organisera une conférence téléphonique pour discuter des résultats financiers du premier trimestre de 2024 le 8 mai 2024. Les parties intéressées peuvent écouter en direct sur le site web de l'entreprise.
MannKind (Nasdaq: MNKD) wird am 8. Mai 2024 einen Konferenzanruf abhalten, um die Finanzergebnisse des ersten Quartals 2024 zu besprechen. Interessierte Parteien können auf der Website des Unternehmens live zuhören.
Positive
  • None.
Negative
  • None.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2024 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 8, 2024.

Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://investors.mannkindcorp.com/events-and-presentations under Events & Presentations.

About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, Twitter or Instagram.

For MannKind:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com


FAQ

When will MannKind release its 2024 first quarter financial results?

MannKind will release its 2024 first quarter financial results on May 8, 2024.

What time will the conference call to discuss the financial results be held?

The conference call to discuss the financial results will be held at 5:00 PM (Eastern Time) on Wednesday, May 8, 2024.

Where can interested parties listen to the conference call live?

Interested parties can listen to the conference call live via the Internet by visiting MannKind 's website at https://investors.mannkindcorp.com/events-and-presentations under Events & Presentations.

Mannkind Corporation

NASDAQ:MNKD

MNKD Rankings

MNKD Latest News

MNKD Stock Data

1.87B
270.76M
1.83%
56.64%
15.24%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
DANBURY